PL1817006T3 - Liposomalny preparat do doustnego podawania glutationu (zredukowanego) - Google Patents
Liposomalny preparat do doustnego podawania glutationu (zredukowanego)Info
- Publication number
- PL1817006T3 PL1817006T3 PL05851408T PL05851408T PL1817006T3 PL 1817006 T3 PL1817006 T3 PL 1817006T3 PL 05851408 T PL05851408 T PL 05851408T PL 05851408 T PL05851408 T PL 05851408T PL 1817006 T3 PL1817006 T3 PL 1817006T3
- Authority
- PL
- Poland
- Prior art keywords
- glutathione
- reduced
- oral administration
- liposomal formulation
- liposomal
- Prior art date
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52278504P | 2004-11-07 | 2004-11-07 | |
US59499605P | 2005-05-25 | 2005-05-25 | |
US59704105P | 2005-11-06 | 2005-11-06 | |
EP05851408A EP1817006B1 (en) | 2004-11-07 | 2005-11-07 | Liposomal formulation for oral administration of glutathione (reduced) |
PCT/US2005/040308 WO2006060120A2 (en) | 2004-11-07 | 2005-11-07 | Liposomal formulation for oral administration of glutathione (reduced) |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1817006T3 true PL1817006T3 (pl) | 2013-03-29 |
Family
ID=36565495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL05851408T PL1817006T3 (pl) | 2004-11-07 | 2005-11-07 | Liposomalny preparat do doustnego podawania glutationu (zredukowanego) |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1817006B1 (pl) |
JP (2) | JP5112876B2 (pl) |
CA (1) | CA2628777C (pl) |
ES (1) | ES2395555T3 (pl) |
IL (1) | IL182950A (pl) |
PL (1) | PL1817006T3 (pl) |
WO (1) | WO2006060120A2 (pl) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006105155A2 (en) * | 2005-03-29 | 2006-10-05 | Guilford Timothy F | Administration of glutathione (reduced) via intravenous or encapsulated in liposome for treatment of tnf-alpha effects and elu-like viral symptoms |
WO2011036557A1 (en) * | 2009-09-22 | 2011-03-31 | The University Of British Columbia | Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles |
WO2011082283A2 (en) * | 2009-12-30 | 2011-07-07 | Guilford F Timothy | Management of myoclonus with oral liposomal reduced glutathione |
US10016389B2 (en) | 2011-01-05 | 2018-07-10 | Livon Laboratories | Method of making liposomes, liposome compositions made by the methods, and methods of using the same |
WO2013103840A1 (en) * | 2012-01-05 | 2013-07-11 | Guilford Frederick Timothy | Anti-cancer composition and method utilizing 3-bp and liposomal reduced glutathione |
US20150030668A1 (en) * | 2012-01-05 | 2015-01-29 | Frederick Timothy Guilford | Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions |
CA2925546C (en) | 2012-10-29 | 2022-06-14 | The University Of North Carolina At Chapel Hill | Methods and compositions for treating mucosal tissue disorders |
EP2956153A4 (en) * | 2013-02-15 | 2017-03-22 | Your Energy Systems, LLC | Treatment of evolving bacterial resistance diseases including klebsiella pneumoniae with liposomally formulated glutathione |
TWI589308B (zh) | 2014-03-25 | 2017-07-01 | 林信湧 | 一種用於治療帕金森氏症之吸入式醫藥組成物及其備製方法 |
CN110198728A (zh) | 2016-11-17 | 2019-09-03 | 莱诺翁股份有限公司 | 用谷胱甘肽组合物治疗呼吸道疾病和感染 |
JP7339955B2 (ja) | 2017-11-17 | 2023-09-06 | レノビオン インコーポレイテッド | 安定したアスコルビン酸組成物およびそれを使用する方法 |
KR102171719B1 (ko) | 2018-11-14 | 2020-10-29 | 충남대학교산학협력단 | 경구투여용 글루타치온 함유 프로리포좀, 이를 포함하는 약제학적 조성물 및 이의 제조방법 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5746921A (en) * | 1980-09-02 | 1982-03-17 | Green Cross Corp:The | Oral preparation of human blood coagulation factor |
FR2609393A1 (fr) * | 1988-02-23 | 1988-07-15 | Serobiologiques Lab Sa | Composition notamment utile comme matiere de base pour la preparation de compositions pharmaceutiques, notamment dermatologiques et/ou cosmetiques comprenant une substance azotee, notamment aminoacides, oligo- ou polypeptides, proteines, et leurs derives, et composition pharmaceutique ou cosmetique ainsi preparee. |
US5238683A (en) * | 1989-11-24 | 1993-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs |
JP3272736B2 (ja) * | 1991-01-31 | 2002-04-08 | 協和醗酵工業株式会社 | リポソーム製剤 |
IT1257697B (it) * | 1992-04-24 | 1996-02-01 | Lifegroup Spa | N-acil derivati di aminoalcooli come agenti terapeutici attivi sull'edema neurogenico endoneurale a livello del nervo periferico. |
US6764693B1 (en) * | 1992-12-11 | 2004-07-20 | Amaox, Ltd. | Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants |
US5607969A (en) * | 1992-12-24 | 1997-03-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-DOPA ethyl ester to treat Parkinson's disease |
JPH0859503A (ja) * | 1994-08-26 | 1996-03-05 | Teijin Ltd | ペプチド・蛋白質性薬物の経口、経粘膜投与用リポソーム製剤 |
US5500232A (en) * | 1994-10-06 | 1996-03-19 | Bristol-Myers Squibb Company | Calcium fortified beverages |
US5891465A (en) * | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
GB9620504D0 (en) * | 1996-10-02 | 1996-11-20 | Boehringer Ingelheim Ltd | Compositions |
US6369106B1 (en) * | 1996-12-26 | 2002-04-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of ischemic brain injuries with brain targeted anti oxidant compounds |
ATE448782T1 (de) * | 1996-12-31 | 2009-12-15 | Antioxidant Pharmaceuticals Co | Pharmazeutische glutathionpräparate und methoden zu dern verabreichung |
US6756056B2 (en) * | 1997-04-08 | 2004-06-29 | Alan A. Rubin | Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
US5829449A (en) * | 1997-09-19 | 1998-11-03 | Thione International, Inc. | Smoking products containing antioxidants |
US6470894B2 (en) * | 1997-09-19 | 2002-10-29 | Thione International, Inc. | Glutathione, green tea, grape seed extract to neutralize tobacco free radicals |
US5994323A (en) * | 1997-12-31 | 1999-11-30 | P.N. Gerolymatos S.A. | Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof |
US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
FR2777781B1 (fr) * | 1998-04-24 | 2004-04-09 | Rhone Poulenc Rorer Sa | Associations riluzole et l-dopa pour le traitement de la maladie de parkinson |
US6011067A (en) * | 1999-06-11 | 2000-01-04 | Thione International, Inc. | Antioxidant composition for the treatment of psoriasis and related diseases |
JP3989803B2 (ja) * | 2002-09-18 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 食品腐敗菌の増殖抑制方法 |
-
2005
- 2005-11-07 CA CA2628777A patent/CA2628777C/en active Active
- 2005-11-07 JP JP2007539376A patent/JP5112876B2/ja active Active
- 2005-11-07 PL PL05851408T patent/PL1817006T3/pl unknown
- 2005-11-07 EP EP05851408A patent/EP1817006B1/en active Active
- 2005-11-07 ES ES05851408T patent/ES2395555T3/es active Active
- 2005-11-07 WO PCT/US2005/040308 patent/WO2006060120A2/en active Application Filing
-
2007
- 2007-05-03 IL IL182950A patent/IL182950A/en not_active IP Right Cessation
-
2012
- 2012-01-13 JP JP2012005488A patent/JP5571706B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2006060120A3 (en) | 2006-09-14 |
JP2012102138A (ja) | 2012-05-31 |
IL182950A (en) | 2013-10-31 |
CA2628777A1 (en) | 2006-06-08 |
CA2628777C (en) | 2016-09-13 |
EP1817006B1 (en) | 2012-09-05 |
JP5571706B2 (ja) | 2014-08-13 |
WO2006060120A2 (en) | 2006-06-08 |
ES2395555T3 (es) | 2013-02-13 |
EP1817006A4 (en) | 2009-12-02 |
EP1817006A2 (en) | 2007-08-15 |
IL182950A0 (en) | 2007-08-19 |
JP5112876B2 (ja) | 2013-01-09 |
JP2008518976A (ja) | 2008-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL182950A0 (en) | Liposomal formulation for oral administration of glutathione (reduced) | |
IL182967A0 (en) | Liposomal formulation of bortezomib (ps-341) | |
IL177402A0 (en) | Composition for oral administration of tamsulosin hydrochloride | |
EP1757273A4 (en) | PREPARATION FOR ORAL ADMINISTRATION | |
AU2003229555A1 (en) | Oral administration form for difficulty soluble basic active ingredients which are applied orally | |
EP1933862A4 (en) | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | |
IL176519A0 (en) | Directly compressible pharmaceutical composition for the oral administration of cci-779 | |
IL173808A0 (en) | Pharmaceutical liposomal formulations | |
AU2003268087A1 (en) | Liposomal gemcitabine compositions for better drug delivery | |
AU2003282782A8 (en) | Pharmaceutically active lipid based formulation of sn38 | |
EP1755633A4 (en) | ORAL ADMINISTRATION OF PEPTIDE PHARMACEUTICAL COMPOSITIONS | |
HK1107271A1 (en) | Method of enhancing absorptions of transmucosal administration formulations | |
AU2003246978A1 (en) | Pharmaceutical compositions comprising cyclosporin for oral administration | |
IL180031A0 (en) | Stable pharmaceutical formulations of benzimidazole compounds | |
HK1113308A1 (en) | Pharmaceutical formulations of gallium salts | |
IL166337A0 (en) | Oral administration of calctionin | |
EP1755568A4 (en) | FORMULATION WITH CONTROLLED RELEASE FOR ORAL ADMINISTRATION OF METFORMIN | |
HK1102021A1 (en) | Pharmaceutical composition for oral administration of a pyrazol-3- carboxamide derivative | |
AU2003284786A8 (en) | Microemulsion composition for oral administration of biphenyldimethyldicarboxylate | |
AU2003280387A1 (en) | Pharmaceutical formulation comprising azithrocycin monohydrate | |
EP1626697A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION WITH LITHIUM CARBONATE | |
ZA200706110B (en) | Pharmaceutical formulations of gallium salts | |
PL373776A1 (pl) | Doustna kompozycja farmaceutyczna | |
GB0413138D0 (en) | Preparation for oral administration | |
GB0225702D0 (en) | Oral formulation of moisutre-sensitive drugs |